APA (7th ed.) Citation

P, G., K, G., T, D., E, H., S, C., N, S., . . . CL, L. (2026). Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study. Cancers, 18(3), . https://doi.org/10.3390/cancers18030373

Chicago Style (17th ed.) Citation

P, Gupta, et al. "Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study." Cancers 18, no. 3 (2026). https://doi.org/10.3390/cancers18030373.

MLA (9th ed.) Citation

P, Gupta, et al. "Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study." Cancers, vol. 18, no. 3, 2026, https://doi.org/10.3390/cancers18030373.